KalVista Pharma

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

Stock market analysts

News

Initiation

Markets

Analyst Ratings

Trading Ideas

KALV

LNTH

QNCX

This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Super Micro Computer Inc.

Pre-Market Outlook

Movers

INVX

KRNY

MTAL

SMCI

TTSH

Super Micro Computer And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

xr:d:DAFsc26aiRI:2,j:5041054601835708275,t:23082411

Price Target

ADBE

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

COST

NVDA

NXPI

TSLA

NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals Inc

Press Releases

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Comments

KalVista Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga